180 related articles for article (PubMed ID: 21937079)
21. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma.
Takai H; Kato A; Kato C; Watanabe T; Matsubara K; Suzuki M; Kataoka H
Liver Int; 2009 Aug; 29(7):1056-64. PubMed ID: 19141032
[TBL] [Abstract][Full Text] [Related]
22. Expression of Glypican 3 in low and high grade urothelial carcinomas.
Aydin O; Yildiz L; Baris S; Dundar C; Karagoz F
Diagn Pathol; 2015 Apr; 10():34. PubMed ID: 25896897
[TBL] [Abstract][Full Text] [Related]
23. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
Shafizadeh N; Ferrell LD; Kakar S
Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
[TBL] [Abstract][Full Text] [Related]
24. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
25. Roles of Combined Glypican-3 and Glutamine Synthetase in Differential Diagnosis of Hepatocellular Lesions.
Wasfy RE; Shams Eldeen AA
Asian Pac J Cancer Prev; 2015; 16(11):4769-75. PubMed ID: 26107238
[TBL] [Abstract][Full Text] [Related]
26. Glypican 3 overexpression in primary and metastatic Wilms tumors.
Tretiakova M; Zynger DL; Luan C; Andeen NK; Finn LS; Kocherginsky M; Teh BT; Yang XJ
Virchows Arch; 2015 Jan; 466(1):67-76. PubMed ID: 25366870
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of antiglypican-3 therapy as a promising target for amelioration of hepatic tissue damage in hepatocellular carcinoma.
Zaghloul RA; El-Shishtawy MM; El Galil KH; Ebrahim MA; Metwaly AA; Al-Gayyar MM
Eur J Pharmacol; 2015 Jan; 746():353-62. PubMed ID: 25449037
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic accuracy of glypican-3 in differentiating hepatocellular carcinoma from metastatic liver tumours.
Majeed S; Mushtaq S; Azam M; Akhtar N; Hussain M; Loya A
J Pak Med Assoc; 2018 Jul; 68(7):1029-1031. PubMed ID: 30317296
[TBL] [Abstract][Full Text] [Related]
29. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
[TBL] [Abstract][Full Text] [Related]
30. Glypican 3 expression in tumors with loss of SMARCB1/INI1 protein expression.
Kohashi K; Nakatsura T; Kinoshita Y; Yamamoto H; Yamada Y; Tajiri T; Taguchi T; Iwamoto Y; Oda Y
Hum Pathol; 2013 Apr; 44(4):526-33. PubMed ID: 23084579
[TBL] [Abstract][Full Text] [Related]
31. Embryonal (undifferentiated) sarcoma of the liver with peripheral angiosarcoma differentiation arising in a mesenchymal hamartoma in an adult patient.
Tucker SM; Cooper K; Brownschidle S; Wilcox R
Int J Surg Pathol; 2012 Jun; 20(3):297-300. PubMed ID: 22134632
[TBL] [Abstract][Full Text] [Related]
32. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer.
Shirakawa H; Kuronuma T; Nishimura Y; Hasebe T; Nakano M; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kobayashi N; Kinoshita T; Nakatsura T
Int J Oncol; 2009 Mar; 34(3):649-56. PubMed ID: 19212669
[TBL] [Abstract][Full Text] [Related]
33. Undifferentiated embryonal sarcoma with unusual features arising within mesenchymal hamartoma of the liver: report of a case and review of the literature.
O'Sullivan MJ; Swanson PE; Knoll J; Taboada EM; Dehner LP
Pediatr Dev Pathol; 2001; 4(5):482-9. PubMed ID: 11779051
[TBL] [Abstract][Full Text] [Related]
34. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z
Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053
[TBL] [Abstract][Full Text] [Related]
35. Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma.
Gong L; Wei LX; Ren P; Zhang WD; Liu XY; Han XJ; Yao L; Zhu SJ; Lan M; Li YH; Zhang W
PLoS One; 2014; 9(1):e87120. PubMed ID: 24498024
[TBL] [Abstract][Full Text] [Related]
36. Oncofetal protein glypican-3 in testicular germ-cell tumor.
Ota S; Hishinuma M; Yamauchi N; Goto A; Morikawa T; Fujimura T; Kitamura T; Kodama T; Aburatani H; Fukayama M
Virchows Arch; 2006 Sep; 449(3):308-14. PubMed ID: 16896894
[TBL] [Abstract][Full Text] [Related]
37. Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma.
Yan B; Wei JJ; Qian YM; Zhao XL; Zhang WW; Xu AM; Zhang SH
Ann Diagn Pathol; 2011 Jun; 15(3):162-9. PubMed ID: 21371925
[TBL] [Abstract][Full Text] [Related]
38. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
Li J; Wei L
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
[TBL] [Abstract][Full Text] [Related]
39. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
[TBL] [Abstract][Full Text] [Related]
40. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary.
Esheba GE; Pate LL; Longacre TA
Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]